QL2107 is named as an intervention in 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Qilu Pharmaceutical Co., Ltd. The most-studied condition is Advanced Solid Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
NCT06754644 · ClinicalTrials.gov ↗ · NSCLC
|
Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | China |
|
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
NCT06911827 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | China |
|
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1/2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Qilu Pharmaceutical Co., Ltd. | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name QL2107 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Qilu Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how QL2107 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how QL2107 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists QL2107 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.